EN DE
Watch Bamboos Health Care Holdings Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Bamboos Health Care Holdings Ltd (2293) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Bamboos Health Care Holdings Ltd stock HK$0.34, price HK$0.43, that is 20.0% below the price, quality 62 out of 100. Rating: overvalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Industrials HK · ISIN KYG072191011

BH Bamboos Health Care Holdings Ltd logo Thin data Nov 15, 2026

Bamboos Health Care Holdings Ltd

2293 · HK

Expensive (fair value 20% below the price) and falling price, but solid company: meets 1 of 3 rules.

Get notified free when this changes
Quality 62/100 
Generates free cash flow 
5.9% dividend yield · Sustainable
Thin margins · 9.3% net margin (TTM) 
Moderate moat 45/100 · thin data
Revenue last quarter 10% below a year ago. 
Changed on Oct 30: HK$0.4100 → HK$0.3400 
Fair value HK$0.3400 · Overvalued 
Falling price (downtrend) 
Weak Growth (revenue 5y −9.5 %/yr in HKD) 
Trails peers (5/13) 
Thin data 
⚠ Thinly traded⚠ Small free float
Watch Bamboos Health Care Holdings Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$0.8552 HK$0.3500 Fair Value HK$0.3400 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range HK$0.3500 – HK$0.8552 · fair‑value band HK$0.2600 – HK$0.4300 · the HK$0.4250 price screens above the HK$0.3400 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow Bamboos Health Care Holdings in your weekly email

Every Wednesday you see whether Bamboos Health Care Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Bamboos Health Care Holdings Limited, an investment holding company, provides healthcare staffing solutions in Hong Kong.

Show moreShow less

The company offers outreach case assessment; clinic; private nursing; home care and out-patient escorting; professional home care and rehabilitation assessment; palliative/hospice care at home; home safety assessment and modification; professional rehabilitation equipment rental; and physiotherapy and occupational therapy services.

It also provides marketing and consulting services; and technology promotion and application services. In addition, the company engages in the sale of health-related merchandise; planning and organizing special events; retail business; and operation of vaccination centers.

It serves individuals and institutional clients, including hospitals, social service organizations, and clinics. Bamboos Health Care Holdings Limited was founded in 2009 and is headquartered in Mong Kok, Hong Kong. Bamboos Health Care Holdings Limited is a subsidiary of Gold Empress Limited.

Stock analysis

Bamboos Health Care Holdings Ltd (2293) currently trades at HK$0.4250, while our model-based Fair Value estimate is HK$0.3400, 20% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of HK$0.5050 per share, and 10 of the 23 models we run sit above the HK$0.4250 price.

Bear case: the Dividend Discount group reads lowest at HK$0.1550, and 13 of the 23 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$0.2600 (bear) to HK$0.4300 (bull), the price of HK$0.4250 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 62/100 (solid quality), in the Industrials sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Bamboos Health Care Holdings Ltd reported revenue of HK$66.7M in FY2026 versus HK$140M in FY2022, a compound −17.0%/yr. Reported net income was HK$6.2M in FY2026, compounding −42.9%/yr from FY2022.

Key figures

Market cap HK$170M (≈ $21.7M) Micro · P/E ratio 21.3 · P/S ratio 1.99 · EPS (TTM) HK$0.0200 · Dividend yield 5.9% · Net margin 9.3% · Return on equity 2.6% · Return on assets (EBIT) 12.2% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 45 out of 100 (low confidence).

What moves the price

The share trades about 19% below its 52-week high and 21% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Industrials peers we cover trades at 37% fair-value upside, at −20%, 2293 screens richer than that median.

Fair Value models

Bear HK$0.2600 Fair Value HK$0.3400 Bull HK$0.4300
Price HK$0.4250 · Downside -20.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$0.4300 HK$0.5400 HK$0.7200 80
Growth DCF HK$0.4400 HK$0.5400 HK$0.7100 77
Residual Income HK$0.4100 HK$0.4100 HK$0.4300 76
All 23 models by family
DCF Models
FCF DCF HK$0.4300 HK$0.5400 HK$0.7200 80
5Y Revenue Exit HK$0.3600 HK$0.4700 HK$0.6200 71
5Y EBITDA Exit HK$0.4000 HK$0.5300 HK$0.7000 73
5Y P/E Exit HK$0.3600 HK$0.4600 HK$0.5800 69
10Y Revenue Exit HK$0.3800 HK$0.4700 HK$0.5800 66
10Y EBITDA Exit HK$0.4100 HK$0.5200 HK$0.6300 67
10Y P/E Exit HK$0.3800 HK$0.4700 HK$0.5500 63
Earnings-Based
Graham-Dodd HK$0.1100 HK$0.1800 HK$0.2300 66
EPV HK$0.2500 HK$0.2700 HK$0.2900 70
Dividend Discount
Gordon GGM HK$0.1200 HK$0.1500 HK$0.1800 69
DDM Multi-Stage HK$0.1200 HK$0.1600 HK$0.2000 67
Multiples
P/E Multiple HK$0.2600 HK$0.3400 HK$0.4300 63
P/S Multiple HK$0.2000 HK$0.2600 HK$0.3300 58
P/B Multiple HK$0.7400 HK$0.9900 HK$1.24 55
EV/EBIT HK$0.2800 HK$0.4000 HK$0.5200 62
EV/EBITDA HK$0.2800 HK$0.3900 HK$0.5000 64
EV/Revenue HK$0.1800 HK$0.2900 HK$0.4000 50
Asset-Based
NCAV (Graham) HK$0.2500 HK$0.3400 HK$0.5100 51
Growth DCF
Growth DCF HK$0.4400 HK$0.5400 HK$0.7100 77
Rev-Margin DCF HK$0.3600 HK$0.4700 HK$0.6100 71
Economic Profit
Residual Income HK$0.4100 HK$0.4100 HK$0.4300 76
ROIC Compounder HK$0.2500 HK$0.2700 HK$0.2900 70
Growth Earnings
Growth-Adj P/E HK$0.1800 HK$0.2600 HK$0.3400 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 62/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 23
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 92
Do the profits arrive as real cash?
Financial strength 62
Debt, balance sheet and risk of trouble
Investment 94
Does it invest with discipline instead of growing at any price?
Low Volatility 63
How calm the share price moves, does not count
Price momentum 45
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 26
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−10.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−19.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.5%
Start year 2021 (pandemic). Over 10 years: +2.7% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.2%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−30.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−36.1%
Dividend (yield on the price)5.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−36.1% vs −13.6%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.67% → 17%
Pace: the 5-year rate starts in 2021 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+3.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Hong Kong: IMF forecast 2.1% a year to 2030, 1.8% from 2016 to 2025) that is about +1.6% a year for the price.

2293 screens overvalued: fair value 20% below the price. Compare with Randstad N.V →

Compare Bamboos Health Care Holdings Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Staffing & Employment Services · 87 stocks

Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 62 · Above median
Fair Value upside −20.0% · Bottom 25%
Profitability
Return on equity (12 months) 2.6% · Below median
Return on assets 1.9% · Below median
Net margin (12 months) 9.3% · Top 25%
Operating margin (12 months) 17.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −10.3% · Bottom 25%
Dividend yield (12 months) 5.9% · Above median

Valuation Multiplesvs Staffing & Employment Services median · lower = cheaper

P/E (12 months) 21.3× · Priciest 25%
P/B 0.69× · Cheapest 25%
P/S (12 months) 2.54× · Priciest 25%
Price / free cash flow (fiscal year) 12.0× · Pricier than median
EV/EBITDA 9.0× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)7 · sector 67
FUTURE (revenue growth)0 · sector 19
PAST (return on equity)10 · sector 38
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)100 · sector 69

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Staffing & Employment Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
FESCO Group 600861 ¥12.65 ¥37.95 +200% vs 2293
Shanghai Foreign Service Holding 600662 ¥4.16 ¥7.94 +91% vs 2293
TriNet Group TNET $65.88 $105.41 +60% vs 2293
Korn Ferry, KFY $75.55 $104.11 +38% vs 2293
Randstad N.V RAND €42.74 €58.53 +37% vs 2293
Adecco Group ADEN CHF 26.14 CHF 26.04 +0% vs 2293
Kforce Inc KFRC $55.85 $35.05 −37% vs 2293
ManpowerGroup Inc MAN $46.59 $27.93 −40% vs 2293
Robert Half Inc RHI $42.00 $23.55 −44% vs 2293
Insperity, Inc NSP $50.48 $17.38 −66% vs 2293

Explore undervalued stocks

More undervalued Industrials stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bamboos Health Care Holdings Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Bamboos Health Care Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2293

Frequently asked questions

Is Bamboos Health Care Holdings Ltd (2293) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of HK$0.3400 versus a price of HK$0.4250, about 20% lower (overvalued).
What is the fair value of 2293?
Our model-based fair value for Bamboos Health Care Holdings Ltd is HK$0.3400 (as of Nov 15, 2026), built from audited fundamentals. The current price: HK$0.4250.
What is the quality score of 2293?
Bamboos Health Care Holdings Ltd has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bamboos Health Care Holdings Ltd (2293)?
Our model-based price target is the fair value of HK$0.3400 (as of Nov 15, 2026) from 23 valuation models. Cautious scenario HK$0.2600, optimistic scenario HK$0.4300. It is a calculation from audited fundamentals, not an analyst target.
What is the Bamboos Health Care Holdings Ltd stock forecast for 2026?
Our models put fair value at HK$0.3400, about 20% lower versus a price of HK$0.4250 (overvalued). Cautious scenario HK$0.2600, optimistic scenario HK$0.4300. The calculation is refreshed regularly with new filings.
What is the revenue of Bamboos Health Care Holdings Ltd (2293)?
Bamboos Health Care Holdings Ltd reported trailing-twelve-month revenue of about HK$67.1M (latest available figure, as of Nov 15, 2026).
Does Bamboos Health Care Holdings Ltd pay a dividend?
Bamboos Health Care Holdings Ltd currently shows a dividend yield of 5.88% relative to its recent price (as of Nov 15, 2026).
How much is the dividend of Bamboos Health Care Holdings Ltd (2293) and when is the ex-dividend date?
Bamboos Health Care Holdings Ltd pays a dividend of HK$0.025 per share a year, a dividend yield of 5.9%. The next ex-dividend date is Dec 2, 2026. A dividend has been paid every year since at least 2015. The payout ratio is 125% of earnings. Free cash flow covers the dividend 1.42 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Bamboos Health Care Holdings Ltd (2293)?
For today's price to be fair in a discounted-cash-flow model, Bamboos Health Care Holdings Ltd would have to grow free cash flow by 3.8 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue fell 9.5 % per year. As of Nov 15, 2026.
What discount rate (WACC) does the fair value of 2293 use?
Our models discount Bamboos Health Care Holdings Ltd at 10.3 %: a base by market capitalisation (nano), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bamboos Health Care Holdings Ltd that is +3.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Bamboos Health Care Holdings Ltd (2293) delivered so far?
Over the past 5 years revenue at Bamboos Health Care Holdings Ltd shrank 9.5 % a year. The price currently implies free-cash-flow growth of +3.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bamboos Health Care Holdings Ltd (2293) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Bamboos Health Care Holdings Ltd (+3.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bamboos Health Care Holdings Ltd (2293)?
The free-cash-flow yield on the price is 8.35 %: that much free cash flow Bamboos Health Care Holdings Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bamboos Health Care Holdings Ltd (2293)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bamboos Health Care Holdings Ltd it is HK$0.3400 per share (as of Nov 15, 2026), against a price of HK$0.4250. It is the blended result of 23 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Bamboos Health Care Holdings Ltd stock overvalued or undervalued in 2026?
As of Nov 15, 2026, 2293 trades above its calculated fair value: price HK$0.4250, fair value HK$0.3400, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2293?
No. The price is what the market pays today (HK$0.4250); the fair value is what the company's own numbers justify (HK$0.3400). For Bamboos Health Care Holdings Ltd the two are HK$0.0850 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bamboos Health Care Holdings Ltd worth?
The market values Bamboos Health Care Holdings Ltd at about HK$170M (market capitalisation, as of Nov 15, 2026). Per share that is HK$0.4250; our models calculate a fair value of HK$0.3400 per share.
What do the bullish and bearish scenarios say about 2293?
Our models span a range for Bamboos Health Care Holdings Ltd: cautious scenario HK$0.2600, base HK$0.3400, optimistic HK$0.4300 per share (as of Nov 15, 2026, price HK$0.4250). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2293?
Bamboos Health Care Holdings Ltd trades at a price-to-earnings ratio of 21.3 (as of Nov 15, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$0.3400 is built from several models across several years. Other multiples: P/B 0.7, P/S 2.5, EV/EBITDA 9.0.
How solid is the balance sheet of Bamboos Health Care Holdings Ltd (2293)?
Balance-sheet figures for Bamboos Health Care Holdings Ltd (as of Nov 15, 2026): return on equity 2.6%. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is 2293 from its 52-week high?
Bamboos Health Care Holdings Ltd trades at HK$0.4250, about 19% below its 52-week high of HK$0.5241 and 21% above the low of HK$0.3500 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.3400 is for.
Which stocks are comparable to Bamboos Health Care Holdings Ltd?
From the same area (Industrials) we also value Randstad N.V, Adecco Group, Korn Ferry,, Robert Half Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bamboos Health Care Holdings Ltd stock attractive at the current price?
The data as of Nov 15, 2026: price HK$0.4250, calculated fair value HK$0.3400 (−20%), Quality Score 62/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2293 calculated?
We run Bamboos Health Care Holdings Ltd through 23 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$0.3400 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Bamboos Health Care Holdings Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bamboos Health Care Holdings Ltd (2293)?
The closing price on Nov 10, 2026 was HK$0.4250. Our model-based fair value is HK$0.3400, about 20% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bamboos Health Care Holdings Ltd right now?
Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Bamboos Health Care Holdings Ltd (2293) come from?
Earnings per share at Bamboos Health Care Holdings Ltd fell 4.4 % a year from 2015 to 2026. Broken into its drivers: revenue per share +4.2 %, EBIT margin −7.0 %, tax rate −0.7 %, residual (interest, one-offs) −0.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Bamboos Health Care Holdings Ltd

How large is the market capitalisation of Bamboos Health Care Holdings Ltd (2293)?
The market capitalisation of Bamboos Health Care Holdings Ltd is HK$170M (≈ $21.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bamboos Health Care Holdings Ltd (2293)?
The price-to-sales ratio of Bamboos Health Care Holdings Ltd is 1.99 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bamboos Health Care Holdings Ltd (2293)?
Earnings per share at Bamboos Health Care Holdings Ltd are HK$0.0200 (price ÷ EPS = P/E 21.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bamboos Health Care Holdings Ltd (2293)?
The dividend yield of Bamboos Health Care Holdings Ltd is 5.9% (payout 125%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bamboos Health Care Holdings Ltd (2293)?
The net margin of Bamboos Health Care Holdings Ltd is 9.3% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bamboos Health Care Holdings Ltd (2293)?
The return on equity (ROE) of Bamboos Health Care Holdings Ltd is 2.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bamboos Health Care Holdings Ltd (2293)?
On an EBIT basis the return on assets of Bamboos Health Care Holdings Ltd is 12.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bamboos Health Care Holdings Ltd (2293)?
The operating margin of Bamboos Health Care Holdings Ltd is 17.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bamboos Health Care Holdings Ltd (2293)?
Revenue at Bamboos Health Care Holdings Ltd is down 10.3% versus a year earlier (3y avg −19.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bamboos Health Care Holdings Ltd (2293)?
Earnings per share at Bamboos Health Care Holdings Ltd are down 8.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Bamboos Health Care Holdings Ltd (2293) carry?
The net debt of Bamboos Health Care Holdings Ltd is HK$26.4M (fiscal year 2026, ≈ 1.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Bamboos Health Care Holdings Ltd in the live analysis

One click puts Bamboos Health Care Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.